CSIMarket
 
Alpha Teknova Inc   (TKNO)
Other Ticker:  
 
 
Price: $2.8500 $-0.12 -4.040%
Day's High: $3.03 Week Perf: -5.63 %
Day's Low: $ 2.85 30 Day Perf: -8.65 %
Volume (M): 8 52 Wk High: $ 4.27
Volume (M$): $ 23 52 Wk Avg: $2.73
Open: $3.03 52 Wk Low: $1.62



 Market Capitalization (Millions $) 85
 Shares Outstanding (Millions) 30
 Employees -
 Revenues (TTM) (Millions $) 36
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 12

Alpha Teknova Inc
Alpha Teknova Inc is a technology company specializing in product development and innovation. The company focuses on providing cutting-edge solutions for various industries including biotechnology, pharmaceuticals, and research. Alpha Teknova Inc aims to deliver high-quality products, such as reagents, enzymes, and assays, that meet the needs of its clients and contribute to advancements in science and medicine. The company is known for its commitment to innovation, quality, and customer satisfaction.


   Company Address: 2451 Bert Dr. Hollister 95023 CA
   Company Phone Number: 637-1100   Stock Exchange / Ticker: NASDAQ TKNO
   TKNO is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Alpha Teknova Inc

Alpha Teknova Inc's Profits Plunge in Financial Q3 of 2023, Reflecting Challenging Times

In a recent announcement, Alpha Teknova, Inc. (Teknova) revealed its plans to raise up to $22.9 million through a registered direct offering and private placement. The funds raised will be used to accelerate research and development of life-saving therapies, vaccines, and molecular diagnostics. This strategic move aims to strengthen Teknova's position in the market and support the advancement of life-saving treatments.
Under the definitive agreements, Teknova will issue and sell up to 1,086,485 shares of its common stock in a registered direct offering at a purchase price of $1.85 per share. Additionally, the company has entered into an agreement to sell an additional 11,299,993 shares of common stock at the same purchase price in a private placement. The pricing of the shares in both offerings adheres to Nasdaq rules, based on the consolidated closing bid price.

Shares

Teknova Raises $22.9 Million to Advance Life-Saving Therapies and Research

Published Mon, Sep 18 2023 12:00 PM UTC

Teknova Announces $22.9 Million Offering to Accelerate Research and Development of Life-saving Therapies
HOLLISTER, Calif., Sept. 18, 2023 - Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, revealed today its plans to raise up...

Alpha Teknova Inc

Alpha Teknova Inc's Financial Performance Plunges: Dwindling Revenue and Plummeting Stocks Threaten Future Prospects



Alpha Teknova Inc, a prominent player in the In Vitro & In Vivo Diagnostic Substances sector, has experienced a downturn in its financial performance. With decreasing revenue and a significant decline in stock value, the company faces challenges that may impact its future prospects.
1. Declining Stock Performance:
Over the past five trading days, Alpha Teknova Inc's stock has witnessed a notable decrease of -7.42%. This drop contributes to a year-to-date performance of -43.42%. The company's stock is currently trading on the NASDAQ, dwelling -22.6% below its 52-week average. These figures indicate a downward trend that investors should closely monitor.

Alpha Teknova Inc

Alpha Teknova Inc Struggles Amidst Challenging Earnings Season, Reporting Negative Return on Equity in Q1 2023

Alpha Teknova Inc Reports Negative Return on Equity in 2023 Fiscal Year
Alpha Teknova Inc, a biotechnology and pharmaceuticals company, has reported a cumulative net loss of $-51 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on equity (ROE) of -46.44%. The company ranks at number 2505 in overall ROE ranking, up from 3365 in the previous quarter.
Among 88 other companies within the Biotechnology & Pharmaceuticals industry, Alpha Teknova Inc's ROE is lower. The fiscal interval ending March 31, 2023, witnessed a widened deficit of $-0.31 per share, compared to $-0.20 per share from the year before. However, the Income per Share marginally improved from $-0.47 per share in the previous financial reporting period.






 

Alpha Teknova Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com